Skip to main content
Premium Trial:

Request an Annual Quote

Sengenics to Offer LifeCodexx NIPT in Southeast Asia

NEW YORK (GenomeWeb) – LifeCodexx and Sengenics have partnered to offer LifeCodexx's noninvasive prenatal fetal trisomy PrenaTest in Southeast Asia.

Under the agreement, the PrenaTest will be available to women in Malaysia, Singapore, Thailand, Brunei, Vietnam, the United Arab Emirates, and elsewhere in the Middle East.

"We are very pleased to expand our footprint into Southeast Asia by teaming up with Sengenics with their longstanding expertise in the field of molecular diagnostics services," said LifeCodexx CEO Michael Lutz in a statement, adding that PrenaTest will now be available in almost 50 countries in Europe, the Middle East, and Southeast Asia.

LifeCodexx performs the PrenaTest in its Germany laboratory using next-generation sequencing technology. Going forward, the company plans to switch to an approach that is based on methylation-specific quantitative PCR, for which it recently obtained CE marking.

Sengenics, an immunodiagnostics and therapeutics company, focuses on applications of its Immunome protein array technology, which it acquired from Oxford Gene Technology in 2015.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.